WO2011133696A3 - Methods of suppressing atherosclerosis - Google Patents

Methods of suppressing atherosclerosis Download PDF

Info

Publication number
WO2011133696A3
WO2011133696A3 PCT/US2011/033293 US2011033293W WO2011133696A3 WO 2011133696 A3 WO2011133696 A3 WO 2011133696A3 US 2011033293 W US2011033293 W US 2011033293W WO 2011133696 A3 WO2011133696 A3 WO 2011133696A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
atherosclerosis
suppressing atherosclerosis
suppressing
mammal
Prior art date
Application number
PCT/US2011/033293
Other languages
French (fr)
Other versions
WO2011133696A2 (en
Inventor
Yuqing Huo
Huan Wang
Weiyu Zhang
Original Assignee
Regents Of The University Of Minnesota
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regents Of The University Of Minnesota filed Critical Regents Of The University Of Minnesota
Publication of WO2011133696A2 publication Critical patent/WO2011133696A2/en
Publication of WO2011133696A3 publication Critical patent/WO2011133696A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

The present invention is directed to methods for treating atherosclerosis in a mammal.
PCT/US2011/033293 2010-04-20 2011-04-20 Methods of suppressing atherosclerosis WO2011133696A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32602810P 2010-04-20 2010-04-20
US61/326,028 2010-04-20

Publications (2)

Publication Number Publication Date
WO2011133696A2 WO2011133696A2 (en) 2011-10-27
WO2011133696A3 true WO2011133696A3 (en) 2012-03-08

Family

ID=44583653

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2011/033293 WO2011133696A2 (en) 2010-04-20 2011-04-20 Methods of suppressing atherosclerosis

Country Status (1)

Country Link
WO (1) WO2011133696A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022167778A1 (en) 2021-02-02 2022-08-11 Haiku Therapeutics Ltd Ebselen as adenosine receptor modulator

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4559157A (en) 1983-04-21 1985-12-17 Creative Products Resource Associates, Ltd. Cosmetic applicator useful for skin moisturizing
LU84979A1 (en) 1983-08-30 1985-04-24 Oreal COSMETIC OR PHARMACEUTICAL COMPOSITION IN AQUEOUS OR ANHYDROUS FORM WHOSE FATTY PHASE CONTAINS OLIGOMER POLYETHER AND NEW OLIGOMER POLYETHERS
US4820508A (en) 1987-06-23 1989-04-11 Neutrogena Corporation Skin protective composition
US4992478A (en) 1988-04-04 1991-02-12 Warner-Lambert Company Antiinflammatory skin moisturizing composition and method of preparing same
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
GB9915437D0 (en) 1999-07-01 1999-09-01 Cerebrus Ltd Chemical compounds III

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HSU CHIH W ET AL: "Caffeine and a selective adenosine A2A receptor antagonist induce sensitization and cross-sensitization behavior associated with increased striatal dopamine in mice", JOURNAL OF BIOMEDICAL SCIENCE, KLUWER ACADEMIC PUBLISHERS, DO, vol. 17, no. 1, 15 January 2010 (2010-01-15), pages 4, XP021065428, ISSN: 1423-0127 *
WANG HUAN ET AL: "Inactivation of the adenosine A2A receptor protects apolipoprotein E-deficient mice from atherosclerosis.", ARTERIOSCLEROSIS, THROMBOSIS, AND VASCULAR BIOLOGY JUL 2009 LNKD- PUBMED:19407243, vol. 29, no. 7, July 2009 (2009-07-01), pages 1046 - 1052, XP055007626, ISSN: 1524-4636 *

Also Published As

Publication number Publication date
WO2011133696A2 (en) 2011-10-27

Similar Documents

Publication Publication Date Title
HK1257823A1 (en) Metalloenzyme inhibitor compounds
HK1198163A1 (en) Metalloenzyme inhibitor compounds
HK1198651A1 (en) Metalloenzyme inhibitor compounds
EP2723731A4 (en) Metalloenzyme inhibitor compounds
EP2563771A4 (en) Metalloenzyme inhibitor compounds
GB201007192D0 (en) Torrefaction process
EP2638021A4 (en) Metalloenzyme inhibitor compounds
EP2628153A4 (en) Method of linguistic profiling
ZA201303466B (en) Method to enhance fiber bridging
EP2616589A4 (en) Method for improving the removal of water
WO2011137427A9 (en) Compositions and methods for treating pulmonary conditions
EP2632903A4 (en) Metalloenzyme inhibitor compounds
GB201013432D0 (en) Method of authentication
EP2651905A4 (en) Metalloenzyme inhibitor compounds
ZA201309109B (en) Methods of treating biomass
EP2751117A4 (en) Metalloenzyme inhibitor compounds
EP2723346A4 (en) Compositions and methods useful for treating pediculosis
WO2011133696A3 (en) Methods of suppressing atherosclerosis
GB201120494D0 (en) Modified exonuclease
AU2010901418A0 (en) Method of pre-treatment
AU2012905493A0 (en) A method of treating wood
AU2011902775A0 (en) Treatment of radiata pine
AU2011902717A0 (en) Treatment of radiata pine
AU2010901808A0 (en) Method of treating water
PL392117A1 (en) Method for the removal of larger trees

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11719115

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11719115

Country of ref document: EP

Kind code of ref document: A2